E
IDH2 and the Krebs cycle Source: Yang et al., 2012

Promising new targeted cancer agents emerge at AACR 2014

Exciting new data was seen at AACR this year, including a novel ADC with a new target in melanoma, a metabolic target and understanding adaptive resistance to PI3K in breast cancer.

April 17, 2014
E
Source: Qiagen

Next generation FGFR inhibitors are early but promising in selected cancers

After disappointing results from FGFR inhibitors brivanib and dovitinib, can the next generation compounds overcome scepticism and offer better efficacy?

April 16, 2014
E
immune checkpoints

Insights from AACR on immunotherapy and checkpoint inhibitors

Immunotherapy is coming of age despite the chequered history in the past with vaccines. In part 1 we explore the state of play in lung cancer.

April 15, 2014
E
Rick Young at AACR 2014

Super Enhancers – what are they and why do they matter in cancer research?

Understanding the regulatory circuitry that controls cell state and differentiation may turn out to be groundbreaking research that changes the way we think about targeting and treating cancer.

April 14, 2014
E
sunrise over san diego

Pfizer’s palbociclib data in ER+ breast cancer – hit or miss?

Pfizer's palbociclib showed promising survival data at the AACR annual meeting this weekend, but is it enough to garner approval on the basis of the phase II data?

April 8, 2014
E
MSKCC Trial Suspensions

The real story behind Juno’s CAR T cell therapy suspensions

This weekend at AACR a controversy emerged on the safety of Juno's CAR T cell therapy.

April 6, 2014
E
Screenshot 2014-04-02 13.29.39

Innate immunotherapy – is it ready for prime time in cancer research?

A review of innate immunotherapies including CD47, KIR, MICA and anti-glucan data at AACR in San Diego.

April 2, 2014
E
JNK_Pathway

Novel targets and approaches in triple negative breast cancer

What are the new targets and drug combinations that are emerging in triple negative breast cancer (TNBC)? find out more about the promising developments in this field.

April 1, 2014
E
Clovis Oncology CO-1686 ELCC 2014

AACR 2014 Preview: Novel targets and approaches

Review of some interesting cancer pipeline drugs at AACR 2014 including TKIs and ADC therapies.

March 27, 2014
E
mtor pathway

What can we learn from exceptional responders in cancer trials?

Following on from yesterday’s post on the potential for small basket trials in ER+ breast cancer with…

March 26, 2014
E
Source: Nature

Do ESR1 mutations drive endocrine resistance during the progression of ER+ breast cancer?

Today brings the launch of our series on the AACR annual meeting Previews.  A variety of different…

March 25, 2014
E
AACR MT Boston

Update on overcoming resistance in metastatic melanoma

What new clinical approaches are being investigated to overcome resistance in melanoma?

March 20, 2014
E
CDK4/6 inhibition - Source: Lilly

CDK inhibitors: will palbociclib and LEE011 make it to market in breast cancer?

Cell cycle inhibitors have been shown to have utility in cancer treatment. A new subclass is emerging to target CDK4/6 with more specificity and less toxicity.

March 19, 2014
E
ISPY2 trial plan

On neratinib in neoadjuvant breast cancer

Puma Biotech are expected to present the neoadjuvant data from ISPY2 for their pan HER inhibitor, neratinib, so what's the deal?

March 14, 2014
E
south pointe

MBCC: Will NGS change the way we treat metastatic breast cancer?

Dr Debu Tripathy presented one of the highlights of the MBCC conference - how we can use genomics to improve clinical trials in TNBC and MBC.

March 13, 2014
E
MBCC14

MBCC: Changing the way we approach advanced breast cancer

Can therapy for advanced breast cancer be individualized using proteomics and genomics data?

March 12, 2014
E
Source: James Kochendefer, NCI

Will CAR T cells give new therapies for NHL and CLL a run for their money?

Much has been written about CAR T cells in B cell leukemias, but what about B cell lymphomas? Kite and the NCI had the honour of being the first to present data from ASH on their therapy in refractory DLBCL lymphomas

March 6, 2014
E
MET Pathway

MetMab fails in phase III advanced lung cancer trial

Nearly 4 years on from the original phase 2 data at ESMO, and we learn that MetMab (onartuzumab) did not meet it's endpoint in the interim analysis of lung cancer patients with MET expression.

March 3, 2014
E
Logo of American Society of Hematology

ASH 2013: Is carfilzomib associated with increased cardiovascular events?

There has been much debate about the cardiovascular risks associated with proteasome inhibitors in multiple myeloma, but what does the data show? A synopsis of the ASH 2013 data and what we can learn in the future...

February 14, 2014
E
Bertrand Tombal ASCO GU 2013

ASCO GU 2014: Will there be a market for Medivation’s enzalutamide in M0 prostate cancer?

The new race to market in advanced prostate cancer is in the M0 asymptomatic space. Several AR antagonists are competing to run trials here but will they lead to men living longer or not?

February 10, 2014
E
Anti-CTLA-4 ipilimumab

Update on immuno-oncology and biomarkers of response

ASCO GU saw an update on the ipilimumab study in post chemotherapy CRPC. New biomarker data published this week in melanoma may be potentially useful in prostate and other tumour types.

February 5, 2014
E
Screenshot 2014-02-04 15.14.55

ASCO GU 2014 Optimal targeting of anti PD-1 and PD-L1 therapies in renal cancer

Update on progress with anti-PD1 and PD-L1 immunotherapies in renal cell cancer. Where is the field going in this space?

February 4, 2014
E
Andrew Armstrong ASCO GU Title Slide

ASCO GU 2014 Beyond Enzalutamide and Abiraterone – What’s Next?

Cross resistance between enzalutamide and abiraterone means that new prostate cancer drugs and targets are needed.

January 31, 2014
E
San Francisco Coit Tower

ASCO GU 2014: Will Galeterone make it to market in Prostate Cancer?

At ASCO GU 2014 Tokai Pharmaceuticals report data for the ARMOR2 trial with reformulated galeterone (TOK-001) in men with prostate cancer. Is this drug likely to make it to market?

January 30, 2014
E
GU14 MDVN PREVAIL

ASCO GU Interview with Dr Tom Beer on Medivation PREVAIL trial data

Enzalutamide significantly decreases the risk of death and delays progression in the PREVAIL trial

January 28, 2014
E
San Francisco Embarcadero

ASCO GU 2014: Why does the Medivation PREVAIL trial matter?

At ASCO GU this week, the clinical data will be presented for the Medivation/Astellas PREVAIL phase III clinical trial of enzalutamide (Xtandi) in men with advanced prostate cancer prior to chemotherapy. The results of this trial not only have important commercial implications for Medivation/Astellas but for competitors in the prostate cancer market.

January 27, 2014
E
Source: Roche

Update on anti-PD-L1 cancer immunotherapy

Roche Genentech are developing their anti-PD-L1 as both monotherapy and also in combination with targeted therapies in lung, melanoma, renal and colon cancers. How is the early development progressing?

January 22, 2014
E
Title Slide ASCO GI Keynote

ASCO GI Keynote: The future of Immunotherapy is Combinations

“We are at beginning of a REVOLUTION in immunotherapy,” said Elizabeth M. Jaffee, MD at the start of American Society of Clinical Oncology GastroIntestinal (ASCO GI) symposium keynote lecture on Immunologic Treatments for GI Cancers.

January 21, 2014
E
Clovis Oncology JPM 2014

Update on CO-1686 and AZD9291 race to market in T790M NSCLC

Update from JP Morgan Healthcare 2014 on Clovis Oncology and AstraZeneca race to market with new drugs for treatment of T790M positive non-small cell lung cancer.

January 15, 2014
E
AGIOS ASH Slide

Can Agios score a winner with their anti-cancer metabolism molecules?

Agios Pharmaceuticals is focused on developing new therapies that target mutations in cancer metabolism, including IDH 1 and 2 for AML and Glioblastoma. Will they be successful despite the huge complexity involved in the underlying processes?

January 13, 2014
E
CAR T Cells

ASH 2013 Stunning ALL data with Novartis CTL019 CAR Therapy

UPenn and CHOP are using genetically modified chimeric antigen receptor (CAR) T cells to treat patients with B cell cancers such as ALL, B cell NHL, CLL and other B cell malignancies. At ASH, the impressive data from adult and pediatric ALL was presented. This post includes insights on this approach and an interview with Dr Stephan Grupp on the pediatric data.

January 9, 2014
E
Foundation Medicine ASH 2013

Insights on Foundation Medicine and how molecular testing will transform cancer research

Increasingly, we are seeing the evolution of diagnostic tests in cancer research. Foundation Medicine are using their gene sequencing platform to identify actionable mutations and assist oncologists make better treatment decisions for their patients.

January 8, 2014
E
Screen Shot 2014-01-07 at 11.22.26 AM

New Immunotherapy data at IASLC Lung Cancer Meeting

Immunotherapy continues to be a hot topic in oncology with anti-PD-1 and other new approaches being discussed at the AACR-IASLC meeting in San Diego

January 7, 2014
E
EXEL Share Price Jan 6 2014

Will Exelixis Cabozantinib COMET-1 prostate cancer trial be positive?

The share price of Exelixis ($EXEL) is starting a run-up (after months in the doldrums) in advance of anticipated results from the COMET-1 phase 3 trial in metastatic castrate resistant prostate cancer (mCRPC) for cabozantinib (Cometriq, formerly XL184). Cabozantinib has been shown to significantly improve bone scans and decrease pain, but will it show an improvement in OS?

January 6, 2014
E
St Jude Penn Legal Case Citation

Juno Therapeutics takes on Penn in dispute over St Jude Chimeric Antigen Receptor Patent

Start-up Juno Therapeutics is now in control of a legal dispute between St Jude Children’s Hospital and the University of Pennsylvania over chimeric antigen receptor (CAR) T cells intellectual property that contributed to the development of CTL019 licensed by Penn to Novartis. Penn are seeking to invalidate a St Jude patent that if upheld, CTL019 may infringe.

January 6, 2014
E
San Francisco ASCO GI Cancer Symposium 2013

ASCO GI 2014 Preview: Pancreatic and Gastric Cancer

Preview of some of the key data being presented at ASCO GI in San Francisco this month.

January 3, 2014
E
San Francisco Golden Gate Bridge

ASCO GU 2014 Prostate Cancer Preview #GU14

ASCO GU symposium takes place at the San Francisco Marriott Marquis from Jan 20 – February 1, 2014. This preview discusses data to be presented on enzalutamide (Xtandi), abiraterone (Zytiga), ODM-201, ARN-509, ipilimumab (Yervoy).

December 30, 2013
E
ASH 2013 Poster Hall

ASH 2013 – gems from the poster halls

There are some 5,000 abstarcts at ASH, many of them posters - what were the interesting nuggets this year?

December 18, 2013
E
BCR Signaling

ASH 2013: New BTK Inhibitor ONO-4059 shows early promise in CLL – is it a future competitor to ibrutinib?

BTK inhibition in the B cell receptor (BCR) pathway has been an exciting area of development over the last couple of years. What do the new competitors entering this space look like?

December 17, 2013
E
ASH

Winners and Losers in CLL at American Society of Hematology

There was a wealth of new data in CLL at ASH but which companies or drugs were the winners and losers in New Orleans? Find out...

December 16, 2013
E
Renier Brentjens ASH 2013 Disclosure

Juno Therapeutics takes on Novartis and seeks to revolutionize the treatment of blood cancers – an interview with Renier Brentjens

Juno Therapeutics is a start-up company with a mission to revolutionize the treatment of blood cancers through the use of chimeric antigen receptor (CAR) modified T cell therapy. The company recently launched with $120 million of series A funding. One of the scientific founders is Renier Brentjens MD, PhD, the Director of Cell Therapeutics at the Memorial Sloan-Kettering Cancer Center in NYC. He kindly gave an interview while at the ASH annual meeting in New Orleans.

December 13, 2013
E
The Alamo San Antonio

AbbVie’s PARP inhibitor veliparib is highly active in triple negative breast cancer

The first readout from the I-SPY2 neoadjuvant breast cancer trial comes from the veliparib (PARP) arm.

December 13, 2013
E
KIR Occupancy by IPH2101

Will anti-KIR immunotherapy make an impact in hematologic malignancies?

Immuno-oncology is a hot topic at the moment and many new targets are emerging that may be useful in combination. This post discusses Innate Pharma's anti-KIR program in hematologic malignancies.

December 12, 2013
E
San Antonio River Walk

What to watch for at San Antonio Breast Cancer Symposium

A preview of some of the landmark trial data emerging from the 2013 San Antonio Breast Cancer Symposium

December 11, 2013
E
ASH 2013 Annual Meeting

ASH 2013 Novel Treatments for CLL – notes from the road

One of the most interesting oral sessions at ASH 2013 took place on the last day and featured data on novel treatments for CLL. Data was presented on ABT-199, dinaciclib and the CAR-modified T-cell therapies in development by Novartis & Juno Therapeutics.

December 11, 2013
E
ASH 2013 Lymphoma Session

ASH 2013 Novel Agents in Lymphoma – notes from the road

At ASH 2013 data on novel agents for the treatment of lymphoma was presented. This post discusses data for idelalisib in iNHL, SAR245409 in R/R Follicular Lymphoma and BAY-BAY 80-6946 (copanlisib).

December 9, 2013
E
ASH 2013 Letai

ASH 2013 BH3 profiling identifies new targets for Bcl-2 inhibitors

ABT-199 has activity in CLL, but what about other tumor types? Check out this post to find out about a new target with potential.

December 8, 2013
E
ASH 2013 Susan O'Brien CLL CME

ASH 2013 New Horizons in CLL – notes from the road

With many new therapies emerging for the treatment of CLL, what criteria can physicians use to decide which therapy to give a patient?

December 7, 2013
E
NVS Panobinostat

Panobinostat may change Multiple Myeloma Competitive Landscape

Novartis announced this morning that their novel pan-HDAC inhibitor, panobinostat (LBH589) in combination with bortezomib (Velcade) and dexamethasone significantly prolonged progression-free survival (PFS) of patients with Multiple Myeloma in the phase III PANORAMA-1 trial.

December 6, 2013
E
ASH Seattle Genetics Balloons

ASH 2013 Preview: quick note on non-Hodgkin’s and Hodgkin’s lymphomas

Will the B cell signaling drugs work in NHL as well as CLL? What of Adcetris in front-line HL?

December 6, 2013
E
Brentjens CART Slide

ASH 2013 Preview: will new Seattle startup Juno Therapeutics push Novartis and U Penn in CART?

Chimeric Antigen Receptor T cell technology (CART) is an exciting new area, especially in hematologic malignancies. With the formation of a new start-up in Seattle, Juno Therapeutics, things just got very interesting...

December 4, 2013
E
Sunset Miami Beach

ASH 2013 Preview – Chronic Lymphocytic Leukemia (CLL)

A review of the upcoming CLL data from the American Society of Hematology ASH meeting.

December 2, 2013
E
myeloid cells, Source: Wikipedia

ASH 2013 Multiple Myeloma Preview

Comprehensive preview of the new developments in multiple myeloma from ASH 2013.

November 25, 2013
E
Fall NYC Central Park

FDA Breakthrough Therapy Designation Benefits – part 2 of an interview with John Jenkins

FDA Office of New Drugs Director John Jenkins discusses the benefits of the Breakthrough Therapy designation and some of the challenges the agency faces in administering it.

November 26, 2013
E
Washington DC Fall Colors

Understanding the Breakthrough Therapy Designation – Part 1 of an interview with FDA New Drugs Director John Jenkins

John K. Jenkins, MD, Director of the Office of New Drugs, Center for Drug Evaluation and Research at the FDA offers a senior management perspective on what is a breakthrough?

November 15, 2013
E
ASH 2012 Atlanta meeting

ASH 2013 Myelofibrosis Preview

A lot of companies are presenting myelofibrosis data at this year's ASH annual meeting in New Orleans. This preview discusses abstracts for ruxolitinib, INCB039110, momelotinib, fedratinib, BMS-91143, pacritinib, LY2784544, pomalidomide, sonidegib.

November 11, 2013
E
aacr molecular targets boston 2013

The future of cancer research – Part 2

The huge wealth of research at the AACR-NCI-EORTC Boston conference provided a great learning environment of where future research with TKIs is likely to be heading...

November 6, 2013
E
Iwakuni Bridge

The future of cancer research – what I learned from the AACR Targets meeting Part 1

The cancer landscape is rapidly changing, in more ways than people realise. Diagnostics are also of increasing importance in helping to decide which therapies patients should receive to optimize treatment.

November 5, 2013
E
Dr Deepak Sampath, Genentech

Gazyva and ABT-199 in CLL & NHL – an interview with Genentech’s Deepak Sampath

An interview with Dr Deepak Sampath from Genentech on the rational for combining obinutuzumab (GA101) with GDC-0199 (ABT-199) for the treatment of B-cell hematological malignancies such as CLL & non Hodgkin’s lymphoma (NHL).

November 1, 2013
E
Sydney Opera House Harbor Bridge

AstraZeneca leaps over Clovis with AZD9291 data at World Lung Conference

Data presented at the World Lung Cancer conference in Sydney suggests AstraZeneca AZD9291 is now ahead of Clovis Oncology CO-1686 in the race to bring a third-generation epidermal growth factor receptor (EGFR) inhibitor to market that targets the T790M resistance mutation.

October 30, 2013
E
Fall Colors Boston

New insights on checkpoint inhibitors and CART in CLL and solid tumors

An update on checkpoint inhibitors and CART from the AACR-NCI-EORTC Molecular Targets meeting - a lot of exciting possibilities are emerging!

October 25, 2013
E
Fall Boston Colors

Abraxane kills potential of MLN0264 in pancreatic cancer

Following the FDA approval of Abraxane, MLN0264, a novel ADC targeting GCC, may no longer have potential as a therapeutic in pancreatic cancer.

October 21, 2013
E
Charles River Boston October 2013

AstraZeneca ramps up AZD9291 lung cancer clinical development

At the AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics conference, Susan Galbraith, M.D, Ph.D. Head of the Oncology Innovative Medicines Unit at AstraZeneca discussed the rapid development of AZD9291, a potent and selective third-generation EGFR inhibitor.

October 20, 2013
E
Boston Charles River October 2013

Pfizer next gen ALK inhibitor PF-06463922 could replace Xalkori

Preclinical data for PF-06463922 (Pfizer), a next generation ALK inhibitor, with potency for all known Crizotinib ALK resistant mutants and ability to cross the blood brain barrier was presented today at the 2013 International Conference on Molecular Targets and Cancer Therapeutics in Boston.

October 20, 2013
E
MIT Koch

A quick preview of the AACR Molecular Targets Conference

Preview of some of the interesting non-embargoed abstracts from the ACCR-NCI-EORTC Molecular Targets conference in Boston

October 15, 2013
E
IMG_8574

ECCO Day 3: Update on alectinib, PD-L1, PI3K and MEK

Update on ALK (alectinib), PD-L1 (MEDI4736), PI3K (GDC-0980 and BKM120) and MEK (trametinib) inhibitors in solid tumours

September 30, 2013
E
ECCO 2013 Poster Hall

Dr Oliver Sartor shares his thoughts on Prostate Cancer data at ECCO 2013

Dr Oliver Sartor, one of the leading experts in Prostate Cancer shares his thoughts on the prostate cancer data presented at ECCO 2013.

September 30, 2013
E
BMN 673 waterfall plot in BRCA1/2 breast cancer

ECCO Highlights Day 2: Breast and Ovarian Cancer

The latest data on BioMarin's PARP inhibitor BMN 673 in breast and ovarian cancer from ECCO 2013

September 29, 2013
E
ECCO 2013 Bikes

ECCO 2013: AZD9291 shows early promise in T790M NSCLC

Promising preliminary phase 1 data for AstraZeneca’s AZD9291 in T790M+ NSCLC presented today at the European Cancer Congress (ECCO 2013) is good news for lung cancer patients.

September 29, 2013
E
ECCO 2013 Amsterdam

ECCO 2013: Is ODM-201 too late to the prostate cancer party?

At ECCO 2013 in Amsterdam, positive data was presented from the phase 1/2 clinical trial for ODM-201 (Orion) a second generation AR antagonist. In contrast the data for ASP9521 (Astellas), a novel androgen biosynthesis inhibitor was negative.

September 29, 2013
E
Source: Ariad

ECCO 2013 Notes from the Road – Day 1

Update on ipilimumab, AP26113, T-DM1, everolimus and others from Day 1 at the 2013 ECCO meeting in Amsterdam.

September 28, 2013
E
photo credit: Claudio.Ar via photopin cc

Preview of key ALK lung cancer abstracts at ECCO 2013

Review of the key abstracts in EML4-ALK lung cancer abstracts being presented at ECCO 2013 in Amsterdam.

September 23, 2013
E
ECCO 2013 Conference Amsterdam

A top line look at the PD-1 and PD-L1 abstracts at ECCO 2013

A quick review of the check point immunotherapy abstracts from #ECC2013 in Amsterdam.

September 19, 2013
E
With permission from Dr Wolchok

How new approaches in targeted immunotherapy with anti-PD-1 and PD-L1 may change cancer research

Overview of anti-PD-1 and PD-L1 immunotherapies plus ASCO 2013 data in melanoma and lung cancer.

September 18, 2013
E
Ibrutinib Pharmacyclics ASH 2012

Ibrutinib leads the race to CLL 17p deletion market

Earlier this month, Janssen/Pharmacyclics announced they had submitted a New Drug Application (NDA) for FDA approval of ibrutinib, an oral Bruton’s tyrosine kinase inhibitor (BTK) in chronic lymphocytic leukemia (CLL) for the treatment of patients with a deletion of the short arm of chromosome 17 (del17p). Approval later this year or in early 2014 is highly likely given that ibrutinib has already been designated a Breakthrough Therapy by the FDA.

July 29, 2013
E
Takeda Orternel Press Release

Orteronel (TAK-700) fails in Advanced Prostate Cancer

Takeda’s orteronel (formerly known as TAK-700) may be on its way to “dog drug heaven” after an interim analysis of the ECM-PC 5 phase 3 clinical trial showed that men with advanced prostate cancer taking the drug did not live significantly longer (HR 0.894, p=0.226) than those taking an inactive placebo.

July 26, 2013
E
Aragon Pharma Website

JNJ acquisition of Aragon ARN-509 deals a blow to Medivation

Johnson & Johnson (JNJ) just announced the acquisition of privately-held Aragon Pharmaceuticals and the rights to ARN-509 a second-generation androgen receptor antagonist that will be a future competitor to Medivation’s Xtandi.

June 17, 2013
E
Video Interview with Dr Susan O'Brien

ASCO 2013 Video Interview with Dr Susan O’Brien on CLL new drugs in development

It's exciting times in Chronic Lymphocytic Leukemia (CLL) with a lot of new data expected at the forthcoming 2013 annual meeting of the American Society of Hematology (#ASH13) in New Orleans. At ASCO 2013, Dr Susan O'Brien shared her thoughts on several new CLL drugs in development including ABT-199, ibrutinib, idelalisib, AV-292, obinutuzumab and IP-145.

June 10, 2013
E
ASCO 2013 Celgene Pancreatic Cancer Sign

ASCO 2013 Abraxane in pancreatic cancer is a welcome new treatment option

At ASCO 2013 the phase III MPACT trial data for Abraxane in pancreatic cancer was presented. This data was first reported at ASCO GI earlier this year. Abraxane in pancreatic cancer is a welcome new treatment option but it is not a major breakthrough that offers a dramatic shift in outcome.

June 7, 2013
E
ASCO 2013 Annual Meeting

ASCO 2013 Pfizer joins race to develop a Herceptin biosimilar with PF-05280014

At ASCO 2013, there was a lot of interest in a poster on Pfizer's PF-05280014, a potential biosimilar to Herceptin.

June 5, 2013
E
ASCO 2013 CLL New Treatments

ASCO 2013 CLL Runners and Riders in Race to Market #ASCO13

New clinical data on ibrutinib, obinutuzumab, idelalisib, IPI-145, ABT-199 for the treatment of Chronic Lymphocytic Leukemia (CLL) will be presented at ASCO 2013.

May 28, 2013
E
ASCO-2013-Preview-Video

ASCO 2013 Preview Video

ASCO 2013 Preview Video of what's hot at the meeting for cancer new products in immunotherapy, CLL, breast cancer, lung cancer and breast cancer. Includes a MOA of PD-L1.

May 28, 2013
E
AACR 2013 Annual Meeting Washington DC

AACR 2013 Posters offer Insights into Biotech Drug Development

The poster sessions at the 2013 annual meeting of the American Association for Cancer Research (AACR) are not all about mice, and test tubes, but offer insights into biotech drug development, new targets and licensing opportunities.

April 15, 2013
E
White House Washington DC

AACR 2013 posters show potential new Pfizer cancer drugs

My overriding impression of large cap Pharma R&D from the 2013 annual meeting of the American Association for Cancer Research (AACR) was that Novartis and Genentech remain the front-runners in cancer drug development, with Pfizer very much up and coming.

April 12, 2013
E
AACR 2013 Annual Meeting

AACR 2013 GDC-0032 a next generation PI3K Inhibitor shows early promise in breast cancer

GDC-0032 is a next generation PI3K inhibitor that spares the beta-isoform of PI3K. Genentech hypothesize this may reduce some of the undesired side effects such as effects on metabolism, previously seen with pan PI3K inhibitors such as GDC-0941. At AACR 2013 promising early clinical data was presented for GDC-0032 in PI3KCA mutant cancers, especially breast cancer.

April 8, 2013
E
Washington Monument Cherry Blossom

AACR 2013 DMUC5754A is a novel agent for Ovarian Cancer

AACR 2013: A late-breaking clinical trial presentation to watch is LB-290: Targeting MUC16 with the Antibody-Drug Conjugate DMUC5754A in patients with platinum-resistant ovarian cancer. This data will be presented by Joyce Liu, MD, MPH from Dana-Farber Cancer Institute in the Clinical Trials Symposium on Tuesday, Apr 9 at 4.00 pm.

April 7, 2013
E
Tokai Poster Title Crop

What is the potential for galeterone in advanced prostate cancer?

Tokai Pharmaceuticals have yet to show the new formulation of galeterone is safe and effective or that men with advanced prostate cancer live longer when taking the drug compared to taking abiraterone or enzalutamide either sequentially, or in combination. While galeterone may offer an innovative mechanism of action, it is too early to say what potential it may have in the treatment of advanced prostate cancer.

March 6, 2013
E
IMG_88951

Dasatinib fails in Prostate Cancer #GU13

ASCO GU 2013: dasatinib phase 3 clinical trial fails to show any survival benefit in men with advanced prostate cancer when used in combination with docetaxel chemotherapy. However whether there are a subset of advanced prostate cancer patients who might respond to the bone-targeted effects of the drug remains open to question.

February 12, 2013
E
ASCO GU 2013 takes place in Orlando, Florida.

ASCO GU 2013 Prostate Cancer Preview #GU13

At the ASCO GU 2013 meeting in Orlando, Bristol Myers Squibb will publish the results of the dasatinib (Sprycel) phase 3 prostate cancer trial. New data on abiraterone, alpharadin, ARN-509 and enzalutamide is also expected.

February 1, 2013
E
ASH 2012 Ernest Beutler Lecture

ASH 2012: CTL019 chimeric antigen receptor technology emerging as a new leukemia treatment

For many attendees, the most exciting news at the 2012 annual meeting of the American Society of Hematology (ASH) held last December in Atlanta was the prospect of personalized T cell therapy for the treatment of patients with B cell cancers such as chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL).

January 15, 2013
E
ASH 2012 Meeting Atlanta

ASH 2012: ABT-199 shows promise in CLL and MCL

ABT-199 is an exciting new agent in development with potential as a new treatment option for CLL & MCL. It is a potent and selective BCL-2 inhibitor that has been engineered not to cause the dose-dependent thrombocytopenia seen with navitoclax.

January 7, 2013
E
Medivation v University of California IP dispute court docket

Court rules Medivation has no IP rights to Aragon Pharmaceuticals ARN-509 $MDVN

Medivation investors hoping for a windfall will be disappointed to hear that on December 20, 2012 a California judge ruled the company had no rights to what is now known as Aragon Pharmaceuticals ARN-509, a next-generation androgen receptor (AR) antagonist for advanced prostate cancer, similar in chemical structure to enzalutamide (Xtandi)

January 3, 2013
E
Hagop Kantarjian M.D. presented on CML treatment choices at the 2012 Chemotherapy Foundation Symposium in New York

The Evolving CML Market – which drug to give when?

Dr Hagop Kantarjian from The MD Anderson Cancer in Houston discussed chronic myeloid leukemia (CML) treatment options at the 2012 Chemotherapy Foundation Symposium in New York.

November 8, 2012
E
AB Science Logo

AB Science files for Pancreatic Cancer approval

AB Science has filed for European approval of mastinib in pancreatic cancer with the European Medicines Agency based on data that showed masitinib significantly increased survival in a subset of patients with a novel genetic biomarker. Data will be presented at 2013 ASCO GI symposium.

October 18, 2012
E
ODM-201 Trial

ESMO 2012 ODM-201 shows promise as a future competitor to enzalutamide

ODM-201 is a second generation androgen-receptor AR antagonist from Orion Pharma in early stages of clinical development.

September 30, 2012
E
TH-302 ESMO 2012

ESMO 2012: TH-302 Pancreatic Cancer Survival Data Fails to Impress

Results were presented at ESMO 2012 for the TH-CR-404 phase 2 clinical trial that compared the efficacy and safety of TH-302 (Threshold Pharmaceuticals) plus gemicitabine versus gemcitabine alone in patients with untreated advanced pancreatic cancer.

September 30, 2012
E
ODM-201 Orion Pharma

ESMO 2012: ODM-201 a new generation antiandrogen for advanced prostate cancer

One of the late-breaking abstracts that I am looking forward at the forthcoming annual Congress of the European Society for Medical Oncology (ESMO 2012) in Vienna is on ODM-201, a new prostate cancer drug from Orion Pharma.

September 18, 2012
E
Early bionic eye prototype drawing - Image courtesy of Bionics Institute

Innovation in Action: helping people to see again

FDA approves first artificial retina prosthesis, the Argus II from Second Sight. This is not a bionic eye. To date, only crude images can be detected. There is no dramatic restoration of sight or vision, instead retinal prostheses currently only offer the ability to detect light and large shapes. Several companies and research groups including Bionic Vision Australia are working on innovative retinal prostheses that aim to restore some vision.

September 17, 2012
E
ESMO 2012 Congress

ESMO 2012 Vienna Congress Plenary Preview #ESMO12

Preview of late breaking abstracts to be presented in Presidential Symposia at the European Society of Medical Oncology ESMO 2012 Congress in Vienna

September 5, 2012
E
s_cover_n0812

Using CSF Biomarkers for Differential Diagnosis of Neurological Diseases

Swedish researchers describe how a panel of five cerebrospinal fluid (CSF) biomarkers allowed the differential diagnosis of common dementia from Parkinsonian disorders.

August 30, 2012
E
biomarkers-consortium logo

Improving Clinical Trials through the use of Biomarkers

Biomarkers can be used for diagnosis and for monitoring the safety and effectiveness of treatments. They are increasingly becoming important in the selection of patients for clinical trials, and as potential surrogates for clinical endpoints that may take a long time to occur e.g. measuring how long someone will live in a cancer trial (overall survival).

August 29, 2012
E
Human thyroid  with cancer nodules. 
Photo Credit: Dr Jeffrey Norton/NCI

NEJM reports trial of Veracyte thyroid cancer diagnostic test, is it worth $4,200?

Detecting thyroid cancer early and avoiding unnecessary surgery is the potential promise of a new diagnostic test.

June 28, 2012
E
Lake Tahoe Pancreatic Cancer Conference

BAY 86-9766 shows early promise at AACR Pancreatic Cancer Conference

A diagnosis of stage IV pancreatic cancer is pretty much a death sentence. There is, therefore, an unmet need for effective new pancreatic cancer treatments.

June 25, 2012
E
AACR 2012 Annual Meeting Posters Piramal Healthcare

AACR 2012: Promising CML & PI3K compounds from Indian company Piramal Healthcare

Piramal Healthcare presented posters on early-stage drug development compounds, including: P7170, a Phosphoinositide 3-Kinase (PI3K)-mammalian Target of Rapamycin (mTOR) and Activin Receptor-Like Kinase 1 (ALK1) inhibitor & P2745, an orally bioavailable molecule effective in imatinib resistant chronic myeloid leukemia cell lines including those with the T315i mutation.

April 24, 2012
E
Bcl-2 is a signaling pathway for the regulation of apoptosis

AACR 2012: ABT-199 is a new Bcl-2 inhibitor with potential in Chronic Lymphocytic Leukemia

ABT-199, a potent and selective inhibitor of Bcl-2. Steven Elmore from Abbott Laboratories presented impressive early data from an ongoing phase I trial in patients with chronic lymphocytic leukemia (CLL).

April 20, 2012
E
Maha Hussain MD

Cabozantinib Mechanism of Action – Part 3 of an interview with Dr Maha Hussain

Dr Hussain discusses the scientific rationale behind the mechanism of action for cabozantinib, a multi-kinase inhibitor of C-MET, VEGF and others.

March 16, 2012
E
Cabozantinib-Prostate-Cancer-Bone-Effect

Cabozantinib Prostate Cancer Bone Scans – Part 2 of an interview with Dr Maha Hussain

At the 2011 ASCO annual meeting, Dr Hussain presented data from a non-randomized phase 2 trial with cabozantinib that showed dramatic improvements in bone scans before and after treatment.

March 14, 2012
E
Image Source: Exelixis

Cabozantinib & Pain in Prostate Cancer – an interview with Dr Maha Hussain

"My average patient is interested in living longer, not just in controlling their pain." Dr Maha Hussain

March 12, 2012
E
EAU 2012 TAK-700 Orterernol Poster

Update on Orteronel TAK-700 from EAU 2012 Paris #EAU12

Orteronel (TAK-700) is a selective, non-steroidal inhibitor of 17, 20 lyase, a key enzyme involved in the production of androgens such as testosterone. This is a similar mode of action to abiraterone acetate (Zytiga).

February 26, 2012
E
Oliver Sartor MD Tulane

ASCO GU: radium-233 Alpharadin significantly prolongs time to first Skeletal Related Event

radium-223 in bone-metastatic castration resistant prostate cancer patients (CRPC), not only significantly prolonged time to first skeletal related event (SRE), but significantly prolonged 3 out of the 4 SRE components.

January 31, 2012
E
Geoffrey Childs, Ph.D

Challenges with Head and Neck Cancer Drug Development

Low-level expression of micro RNA-375 (miR-375) correlated with poor outcome in tumors of HNSCC patients.

January 25, 2012
E
radium-223-Alpharadin-time-to-first-skeletal-related-event-ALSYMPCA-trial

Preview of ASCO GU 2012 Prostate Cancer Data

My preview of prostate cancer abstracts that caught my attention.

January 20, 2012
E
Radotinib-IY5511-CML-IL-Yang-Pharma-Korea

Radotinib approved in South Korea for CML

The South Korean equivalent of the FDA have approved radotinib (Il-Yang pharmaceuticals) or chronic myeloid leukemia (CML).

January 5, 2012
E
PSA Changes with ODM-201 courtesy of Orion Pharma

AACR 2014: Review of novel targeted approaches in lung and prostate cancers

Overcoming acquired resistance to therapy is a major focus in lung and prostate cancers. Check out the new developments from AACR.

April 22, 2014